|The European Agency for the Evaluation of Medicinal Products|
|Human Medicines Evaluation Unit|
|London, 20 July, 1998|
|Direct Line +44.171.418.8411|
|Mr Charles Medawar|
|Social Audit Ltd|
|P.O. Box 111|
|London NW1 8XG|
Dear Mr Medawar,
I refer to your letter dated 14 July 1998 and the note enclosed on "SSRIs, EMEA, and the CPMP".
As most of the note is an expression of personal opinion it would of course be difficult for me to either agree or disagree.
Nevertheless, I would like to take this opportunity to comment on a few of the points you noted:
I would certainly be interested in the "average doctor or patient" and their understanding of texts presented to them. Numerous investigations have certainly contributed to improving the value of such information, but I do not share your uni-directional interpretation that "withdrawal reactions were of minor significance" as this does not reflect the text of the Summary of Product Characteristics (SPC)
Whereas SPC and Patient Information Leaflet (PIL) have to give information about adverse reactions, where possible their frequency and severity, and the marketing authorisation takes into account such a situation, it is certainly not possible or useful to mention the "unknown" or personal opinions as listed in [a] to [J] of your letter dated 14 July 1998.
Yours sincerely Prof Rolf Bass Head of Human Medicines Evaluation Unit
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Switchboard: (+44-171) 418 8400 Fax: (+44-171) 418 8551 Email: email@example.com http://www.eudra.org/emea.html
CLICK HERE TO READ ON